Latest Breaking News On - Nd krys us5011471027 - Page 1 : comparemela.com

PITTSBURGH, June 22, 2022 Krystal Biotech, Inc. , the leader in redosable gene therapy, announced today the submission of a Biologics License Application to the U.S. Food and Drug. | June 22, 2022

Suma krishnanKrystal biotech incDrug administrationResearch developmentEuropean medical agencyExchange commissionGlobenewswire incBiologics license applicationKrystal biotechMedical agencyDystrophic epidermolysis bullosaRegenerative medicine advanced therapyPrivate securities litigation reform actNc stock exchangePress releaseNd krys us5011471027